Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

Abstract: The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A?, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A?, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.

Abstract: Thiophene-substituted tetracyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2, R3, R4 and R5 are as defined herein. The compositions comprising at least one thiophene-substituted tetracyclic compound, and methods of using the thiophene-substituted tetracyclic compounds for treating or preventing HCV infection in a patient are also provided.

Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: Provided is a method for protecting software. Software license information of an authorized user is used to generate an identifying code of software license. The identifying code of software license is analyzed by the software system of the authorized client terminal wherein the software license information and valid period of said identifying code of software license. The software system of an authorized client terminal then determines whether the current time is within the validation time period. If the current time is within the validation time period, then the protected software is enabled.

Abstract: Provided are a method for displaying the usage of computer resources and a device therefor. The method includes: 1) constructing a rectangular coordinate system with the usage data of two computer resources as the horizontal and vertical axes, respectively; 2) drawing dots in the rectangular coordinate system using the simultaneously obtained usage data of the two computer resources as the coordinates and using colors for the dots determined by the sampling sequence; 3) when a user views the graph, he can approximately determine the usages of the two computer resources at a given time by observing the position of the dot, can approximately determine the duration between the time a given sample is taken and the current time by the color of the dot, and can approximately determine the typical usage state of the computer resources by observing the density of the dots in the graph.

Abstract: The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.

Abstract: A traffic signal control method comprises confirming the shortest green light interval; confirming the conflict area of the different traffic flow and the key conflict point position according to the engineering design for road canalization; confirming the longest clear distance si(m) of the traffic tail unit of green light i and the shortest entry distance sj(m) of the traffic head unit of green light j in conflict with green light i; calculating the longest clear time Max{ti} of the traffic tail unit of green light i and the shortest entry time Min{tj} of the traffic head unit of green light j; calculating the shortest green light interval Iij=A+Max{ti}?Min{tj}; confirming the control scheme for the crossing according to the shortest green light interval and sending the control instruction to the traffic signal display device for displaying in real time according to the control scheme. A traffic signal control system and special equipment are also provided.

Abstract: A traffic signal control method comprises confirming the shortest green light interval; confirming the conflict area of the different traffic flow and the key conflict point position according to the engineering design for road canalization; confirming the longest clear distance si(m) of the traffic tail unit of green light i and the shortest entry distance sj(m) of the traffic head unit of green light j in conflict with green light i; calculating the longest clear time Max{ti} of the traffic tail unit of green light i and the shortest entry time Min{tj} of the traffic head unit of green light j; calculating the shortest green light interval Iij=A+Max{ti}?Min{tj}; confirming the control scheme for the crossing according to the shortest green light interval and sending the control instruction to the traffic signal display device for displaying in real time according to the control scheme. A traffic signal control system and special equipment are also provided.

Abstract: Embodiments of the present invention provide a method and a media gateway for realizing a packet-packet model session. According to an embodiment of the present invention, the media gateway determines whether the session meets the TrFO protocol. In the case that the session doesn't meet the TrFO protocol, the media gateway inserts a pair of back-to-back TCs, activates the pair of back-to-back TCs such that the pair of back-to-back TCs perform the TFO negotiation, thus making the pair of back-to-back TCs work in a pass-through mode. In the embodiments of the present invention, because it is possible to bypass the codec ability of the pair of back-to-back TCs, the voice quality deterioration introduced in the prior art due to adopting the codec conversion may be avoided.

Abstract: A method and code for controlling the operation of a deactivatable valve lifter of an internal combustion engine includes determining an oil viscosity measure based upon an engine oil pressure achieved when the engine is operating at a warm engine idle operating condition; determining a minimum oil temperature for actuator operation based on a comparison of the oil viscosity measure with a stored value representing the oil's nominal viscosity; and enabling actuator operation when an instantaneous oil temperature is not less than the minimum oil temperature.

Abstract: A method and code for controlling the operation of a deactivatable valve lifter of an internal combustion engine includes determining an oil viscosity measure based upon an engine oil pressure achieved when the engine is operating at a warm engine idle operating condition; determining a minimum oil temperature for actuator operation based on a comparison of the oil viscosity measure with a stored value representing the oil's nominal viscosity; and enabling actuator operation when an instantaneous oil temperature is not less than the minimum oil temperature.